Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection DOI Creative Commons
Chiara Farroni,

Anna Maria Gerarda Altera,

A. Salmi

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 13, 2025

Background Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, tuberculosis infection (TBI), have a high probability of progressing to disease (TB). We aim characterize the impact IMID on immune response M. (Mtb) in patients TBI and TB disease. Methods enrolled without IMID. Peripheral blood mononuclear cells (PBMCs) were stimulated Mtb-derived epitopes (MTB300). By flow-cytometry, we identified Mtb-specific CD4 + T cytokine-producing or CD25 CD134 cells. Memory activation status assessed by evaluating: CD153, HLA-DR, CD45RA, CD27. Mycobacterial growth inhibition assay (MGIA) was used evaluate ability PBMCs inhibit mycobacteria growth. A long-term stimulation detect memory response. Results The therapy did not affect magnitude Mtb-antigen number responders. TBI-IMID showed cytokine profile like patients. Mtb characterized an effector central phenotype groups. This allowed increased IFN-γ production after 6 days MTB300-stimulation. HLA-DR expression associated TB, whereas CD153 status. Finally, had MGIA Conclusion condition does key aspects Mtb, response, profile, contain replication. immunological characterization fragile population is fundamental understanding correlation between protection

Language: Английский

Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection DOI Creative Commons
Chiara Farroni,

Anna Maria Gerarda Altera,

A. Salmi

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 13, 2025

Background Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, tuberculosis infection (TBI), have a high probability of progressing to disease (TB). We aim characterize the impact IMID on immune response M. (Mtb) in patients TBI and TB disease. Methods enrolled without IMID. Peripheral blood mononuclear cells (PBMCs) were stimulated Mtb-derived epitopes (MTB300). By flow-cytometry, we identified Mtb-specific CD4 + T cytokine-producing or CD25 CD134 cells. Memory activation status assessed by evaluating: CD153, HLA-DR, CD45RA, CD27. Mycobacterial growth inhibition assay (MGIA) was used evaluate ability PBMCs inhibit mycobacteria growth. A long-term stimulation detect memory response. Results The therapy did not affect magnitude Mtb-antigen number responders. TBI-IMID showed cytokine profile like patients. Mtb characterized an effector central phenotype groups. This allowed increased IFN-γ production after 6 days MTB300-stimulation. HLA-DR expression associated TB, whereas CD153 status. Finally, had MGIA Conclusion condition does key aspects Mtb, response, profile, contain replication. immunological characterization fragile population is fundamental understanding correlation between protection

Language: Английский

Citations

1